

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 98,385-E)

PATENT

RECEIVED

In the Application of:

Hauptmann et al.

Serial No.: 09/525,998

Filing Date: March 15, 2000

For: TNF receptors, TNF binding proteins
and DNAs coding for them



Examiner: To be Assigned

Group Art Unit: 1646

TECH CENTER 100/2900

TRANSMITTAL LETTER

Asst. Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

- In regard to the above identified application,
1. We are transmitting herewith the attached:
 - a) Information Disclosure Statement;
 - b) PTO Form 1449; and cited references
 - c) Return postcard
 2. With respect to fees:
 - a) No fees are required
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
 3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service hand delivered to the Asst. Commissioner for Patents, Washington, D.C. 20231 on October 24, 2000.

Respectfully submitted,

Kevin E. Noonan, Ph.D.
Registration No. 35,303

Date: 24 October 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 98,385-E)

In the Application of:

Hauptmann et al.

Serial No.: 09/525,998

Filing Date: March 15, 2000

For: TNF receptors, TNF binding proteins
and DNAs coding for them



Examiner: To be Assigned

Group Art Unit: 1646

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from

Deposit Account 13-2490.

U.S. Patent Documents

1. 4,289,690	Pestka et al.	Sep. 15, 1991
2. 4,560,649	Saxena et al.	Dec. 24, 1985
3. 4,560,649	Saxena et al.	Dec. 24, 1985
4. 4,578,335	Urdal et al.	Mar. 25, 1986
5. 4,609,546	Hiratani	Sep. 2, 1986
6. 4,675,285	Clark et al.	Jun. 23, 1987
7. 4,789,658	Yoshimoto et al.	Dec. 6, 1988
8. 4,902,502	Nitecki et al.	Feb. 20, 1990
9. 4,904,584	Shaw	Feb. 27, 1990
10. 4,931,544	Katre et al.	Jun. 5, 1990
11. 4,935,233	Bell et al.	Jun. 19, 1990
12. 4,966,888	Saxena et al.	Oct. 30, 1990
13. 5,089,261	Nitecki et al.	Feb. 18, 1992
14. 5,116,964	Capon et al.	May 26, 1992
15. 5,136,021	Dembinski et al.	Aug. 4, 1992
16. 5,153,265	Shadle et al.	Oct. 6, 1992
17. 5,162,430	Sano et al.	May 25, 1993
18. 5,214,131	Harris et al.	Oct. 12, 1998
19. 5,252,714	Harris et al.	Oct. 12, 1993
20. 5,344,915	LeMaire et al.	Sep. 6, 1994
21. 5,359,037	Wallach et al.	Oct. 25, 1994
22. 5,382,657	Karasiewicz et al.	Jan. 17, 1995
23. 5,395,760	Smith et al.	Mar. 7, 1995
24. 5,478,925	Wallach et al.	Dec. 26, 1995
25. 5,512,544	Wallach et al.	Apr. 30, 1996
26. 5,605,690	Jacobs et al.	Feb. 25, 1997
<u>27.</u> 5,610,279	Brockhaus et al.	Mar. 11, 1997
28. 5,633,145	Feldmann et al.	May 27, 1997
29. 5,695,953	Wallach et al.	Dec. 9, 1997
30. 5,712,155	Smith et al.	Jan. 27, 1998
31. 5,808,029	Brockhaus et al.	Sep. 15, 1998



- | | | |
|---------------|------------------|---------------|
| 32. 5,811,261 | Wallach et al. | Sep. 22, 1998 |
| 33. 5,843,791 | Hauptmann et al. | Dec. 1, 1998 |
| 34. 5,863,786 | Feldmann et al., | Jan. 26, 1999 |

FOREIGN PATENTS

35. DE03910323A1

36. DE03913101.7

37. DE0920282.8

38. EP0154316A2

39. EP0154316B1

40. EP0162699

41. EP0225579A3

42. EP0247860A2

43. EP0259863A2

44. EP0308378

45. EP0334165A2

46. EP0393438A2

47. EP0398327A1

48. EP0412486

49. EP0417563A2

50. EP0418014A1

51. EP0422339

52. EP0433900

53. EP0512528A2

54. EP0526905A2

55. GB2218101

56. GB2246569A

57. WO90/13575

58. WO91/03553

59. WO92/01002

60. WO92/07076

61. WO92/13095

- 62. WO92/15682
- 63. WO92/16221
- 64. WO93/01474
- 65. WO94/06476

OTHER DOCUMENTS

- 66. Anderson et al., "Quantitative Filter Hybridisation," *Nucleic Acid Hybridization: A Practical Approach* pp. 73-111 (Hawes et al., eds., 1985).
- 67. Aggarwal et al., "Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon," *Nature* 318:665-67 (1985).
- 68. Baglioni et al., "Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition," *J. Biol. Chem.* 260:13395-97 (1985).
- 69. Bakouche et al., "Plasma membrane-associated tumor necrosis factor. A non-integral membrane protein possibly bound to its own receptor," *J. Immunol.* 140:1142-47 (1988).
- 70. Beutler et al., "Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin," *Science* 229:869-71 (1985).
- 71. Binkert et al., "Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)," *EMBO J.* 8:2497-502 (1989).
- 72. Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," *Science* 247:1306-10 (1990).
- 73. Brennan et al., "Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis," *Lancet* 2:244-47 (1989).
- 74. Brockhaus, M. et al., *Proc. Natl. Acad. Sci. USA* 87:3127-3131 (1990)
- 75. Capaldi et al., "Changes in order of migration of polypeptides in complex III and cytochrome C oxidase under different conditions of SDS polyacrylamide gel electrophoresis," *Biochem. Biophys. Res. Commun.* 74:425-33 (1977).
- 76. Carlino et al., "Use of a Sensitive Receptor Binding Assay to Discriminate Between Full-Length and Truncated Human Recombinant TNF"
- 77. Colletti et al., "The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion," *Transplantation* 49:268-72 (1990).
- 78. Creasy, A. et al., *Proc. Natl. Acad. Sci. USA* 84:3293-3297 (1987)
- 79. Dayer et al., "Purification and Characterization of Human Tumor Necrosis Factor a

Inhibitor," *Chemical Abstracts* 113(38760n):454 (1990).

80. Dembic et al., "Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences," *Cytokine* 2:231-37 (1990).
81. Engelmann et al., "A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity," *J. Biol. Chem.* 264:11974-80 (1989).
82. Engelmann et al., "Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity," *J. Biol. Chem.* 265:14497-504 (1990).
83. Espevik et al., "Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor," *J. Exp. Med.* 171:415-26 (1990).
84. Evans, "The steroid and thyroid hormone receptor superfamily," *Science* 240:889-95 (1988).
85. Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer," *Proc. Natl. Acad. Sci. U. S. A.* 85:8998-9002 (1988).
86. Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin....," *Proc. Natl. Acad. Sci. USA* 87:8781-8784 (1990).
87. Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," *BioTechnology* 8:343-346 (1990).
88. Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," *Mol. Cell. Biol.* 11:3020-26 (1991).
89. Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein," *Proc. Natl. Acad. Sci. U. S. A.* 87:7380-84 (1990).
90. Grizzard et al., "Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus," *J. Clin. Endocrinol. Metab.* 58:535-43 (1984).
91. Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation. Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. Coli," *J. Cell Biochem. Suppl.* 15F:113(1991)
92. Hass et al., "Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts," *J. Biol. Chem.* 260:12214-18 (1985).
93. Hatakeyama et al., "Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's," *Science* 244:551-56 (1989).
94. Hauser et al., "Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6," *Neurology*

40:1735-39 (1990).

95. Heller et al., "Amplified expression of tumor necrosis factor receptor in cells transfected with Epstein-Barr virus shuttle vector cDNA libraries," *J. Biol. Chem.* 265:5708-17 (1990).
96. Himmler et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein," *Dev. Cell Biol.* 9:705-15 (1990).
97. Hofman et al., "Tumor necrosis factor identified in multiple sclerosis brain," *J. Exp. Med.* 170:607-12 (1989).
98. Hohmann, H.P. et al., *J. Biol. Chem.* 264:14927-14934
99. Israel et al., "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," *Immunol. Lett.* 12:217-224(1986).
100. Kasukabe et al., "Purification of a novel growth inhibitory factor for partially differentiated myeloid leukemic cells," *J. Biol. Chem.* 263:5431-35 (1988).
101. Kohno et al., "A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occurring Tumor Necrosis Factor Inhibitor," *Proc. Natl. Acad. Sci. USA* 87:8331-8335 (1990).
102. Kull et al., "Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity," *Proc. Natl. Acad. Sci. U. S. A.* 82:5756-60 (1985).
103. Lantz et al., "Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor," *J. Clin. Invest.* 86:1396-42 (1990).
104. Le et al., "Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities," *Lab. Invest.* 56:234-48 (1987).
105. Lee et al., "Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase," *Science* 239:1288-91 (1988).
106. Lehmann and Droge, "Demonstration of membrane receptors for human natural and recombinant 125I-labeled tumor necrosis factor on HeLa cell clones and their role in tumor cell sensitivity," *Eur. J. Biochem.* 158:1-5 (1986).
107. Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression," *Nature* 330:537-43 (1987).
108. Liao et al., "Identification of a specific interleukin 1 inhibitor in the urine of febrile patients," *J. Exp. Med.* 159:126-36 (1984).
109. Liao et al., "Characterization of a Human Interleukin 1 Inhibitor," *J. Immunol.* 134(6):3882-3886 (1995).
110. Liblau et al., "Tumor Necrosis Factor- α and Disease Progression in Multiple Sclerosis,"

New Engl. J. Med. 326(4):272-273 (1992)

111. Lindvall et al., "Modulation of the constitutive gene expression of the 55 kD tumor necrosis factor receptor in hematopoietic cells," *Biochem. Biophys. Res. Commun.* 172:557-63 (1990).
112. Loetscher et al., "Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity," *J. Biol. Chem.* 266:18324-29 (1991).
113. March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs," *Nature* 315:641-47 (1985).
114. Neda, Hiroshi, "Analysis of the Tumor Necrosis Factor (TNF) Receptor of Various Tumor Cells," *Tumor Necrosis Factor, (TNF) Receptor* 56(2):305-17 (1987).
115. Nexl et al., "Lectin-agarose immobilization, a new method for detecting soluble membrane receptors. Application to studies with epidermal growth factor-urogastrone and transcobalamin-II," *J. Biol. Chem.* 254:8740-43 (1979).
116. Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA of the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," *The EMBO J.* 9(10):3269-3278 (1990).
117. Novick et al., "Soluble cytokine receptors are present in normal human urine," *J. Exp. Med.* 170:1409-14 (1989).
118. Novick et al., "Soluble Cytokine Receptors are Present in Normal Human Urine," *The Physiological and Pathological Effects of Cytokines* pp. 413-21 (1990).
119. Novick et al., "Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography," *J. Chromatogr.* 510:331-37 (1990).
120. Olsson et al., "Isolation and characterization of a tumor necrosis factor binding protein from urine," *Eur. J. Haematol.* 42:270-75 (1989).
121. Peetre, C. et al., *Eur. J. Haematol* 41:414-419 (1988)
122. Peppel et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," *J. Exp. Med.* 174:1483-1489 (1991).
123. Piguet et al., "Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis," *J. Exp. Med.* 170:655-63 (1989).
124. Powell et al., "Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity," *Int. Immunol.* 2:539-44 (1990).
125. Rhein et al., "Another Sepsis Drug Down--Immunex TNF Receptor," *Biotechnology Newswatch*, pg. 1,3 (Monday, October 4, 1993).

- 126 Ruddle et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," *J. Exp. Med.* 172:1193-1200 (1990).
- 127 Schall, T. J. et al., *Cell* 61:361-370 (1990)
- 128 Scheurich et al., "Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines," *Int. J. Cancer* 38:127-33 (1986).
- 129 Seckinger et al., "Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor," *Proc. Natl. Acad. Sci. U. S. A.* 87:5188-92 (1990).
- 130 Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor," *J. Biol. Chem.* 264:11966-73 (1989).
- 131 Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor Alpha," *J. Exp. Med.* 167:1511-1516.
- 132 Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor α ," *J. Immunol.* 139(5):1541-1545(1987).
- 133 Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor α ," *J. Immunol.* 139(5):1446-1549(1987)
- 134 Selmaj et al., "Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor," *J. Immunol.* 144:129-35 (1990).
- 135 Selmaj and Raine, "Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro," *Ann. Neurol.* 23:339-46 (1988).
- 136 Shimizu et al., *PNAS USA*, 80:2112-2116 (1983).
- 137 Smith et al., "Species specificity of human and murine tumor necrosis factor. A comparative study of tumor necrosis factor receptors," *J. Biol. Chem.* 261:14871-74 (1986).
- 138 Smith et al., *Science* 248:1019-1023(1990)
- 139 Socher et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor," *Proc. Natl. Acad. Sci. U. S. A.* 84:8829-33 (1987).
- 140 Spinaz et al., "Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans," *Am. J. Physiol.* 259(5 Pt 2):R993-7 (1990).
- 141 Stauber and Aggarwal, "Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937," *J. Biol. Chem.* 264:3573-76 (1989).
- 142 Stauber, G. et al., *J. Biol. Chem.* 263(35):19098-19104.
- 143 Suffys et al., "Involvement of a serine protease in tumour-necrosis-factor-mediated

- cytotoxicity." *Eur. J. Biochem.* 178:257-65 (1988).
- 144 Suggs et al., "Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin." *Proc. Natl. Acad. Sci. U. S. A.* 78:6613-17 (1981).
- 145 *The Cytokine Factsbook* pp. 244-46 (Callard, ed., Academic Press, 1994).
- 146 Tracey et al., "Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation." *J. Exp. Med.* 167:1211-27 (1988).
- 147 Tracey et al., "Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia." *J. Clin. Invest.* 86:2014-24 (1990).
- 148 Tracey et al., "Physiological responses to cachectin." *Tumor Necrosis Factor and Related Cytotoxins* pp. 88-108 (Ciba Foundation Symposium 131, Wiley, Chichester, 1987).
- 149 Tracey et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia." *Nature* 330:662-664(1987).
- 150 Tsujimoto et al., "Physiological responses to cachectin, "Tumor necrosis factor and related cytotoxins. Wiley, Chichester (Ciba Foundation Symposium 131), pp. 88-108 (1987).
- 151 Unglaub et al., "Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators." *J. Exp. Med.* 166:1788-97 (1987).
- 152 Vilcek et al., "Tumor necrosis factor: receptor binding and mitogenic action in fibroblasts." *J. Cell. Physiol.* 5:57-61 (1987).
- 153 Vitt et al., "Biological and Structural Characterization of the Tumor Necrosis Factor Receptor on Multiple Cell Types: Relationship to Function," *Fed. Proc. 78th Annual Meeting of the American Society of Biological Chemists* 46(6):2117 (1987).
- 154 Wallach et al., "Mechanisms which take part in regulation of the response to tumor necrosis factor," *Lymphokine Res.* 8:359-63 (1989).
- 155 Wallach, "Preparations of lymphotoxin induce resistance to their own cytotoxic effect." *J. Immunol.* 132:2464-69 (1984).
- 156 Wallach et al., "Regulation of the Response to Tumor Necrosis Factor." pp. 134-47 (Bonavida et al., eds., *Tumor Necrosis Factor/Cachectin and Related Cytokines Int. Conf. Tumor Necrosis Factor and Related Cytotoxins, Heidelberg.* 1987).
- 157 Walsh et al., "Isolation and purification of ILS, an interleukin 1 inhibitor produced by human gingival epithelial cells." *Clin. Exp. Immunol.* 68:366-74 (1987).
- 158 Weber et al., "Production of an epidermal growth factor receptor-related protein." *Science* 224:294-97 (1984).

159. Yoshie et al., "Binding and Crosslinking of 125 I-labeled Recombinant Human Tumor Necrosis Factor to Cell Surface Receptors," *J. Biochem.* 100:531-541 (1986).

160. Ziegler, "Tumor necrosis factor in humans," *N. Engl. J. Med.* 318:1533-35 (1988).

Date: 24 October 2000

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Kevin E. Noonan, Ph.D.

Reg. No. 35,303